As we progressed our first-year agenda, we saw precision health, underpinned by genomics, benefiting individuals, families, carers, and the health system more broadly. The community’s understanding of genomics was essential to allowing the swift development of vaccines, diagnostics, tests and as a tool for epidemiologists.

In its 2022 election statement, InGeNA says the incoming government has the opportunity to build on Australia’s growing genomics expertise and enable consumers to benefit from the new age of precision health.

As our healthcare system transitions from a specialist and disease-centred system to a learning healthcare system driven by precision medicine, the competencies and capabilities of the various workforces servicing this sector also need to change

InGeNA commissioned Deloitte Access Economics to conduct research which will provide a snapshot of the potential value of genomics on healthcare in Australia by profiling a suite of case study applications across the screening, diagnosis, and treatment stages of the care continuum.

The InGeNA Strategic Plan highlights the breadth and range of industry groups committed to working together to bring a shared perspective on critically important areas underpinning the future of genomics.